Media Articles Related to Thymoglobulin (Anti-Thymocyte Globulin)
Protein that repels immune cells protects transplanted pancreatic islets from rejection
Source: Transplants / Organ Donations News From Medical News Today [2015.02.19]
Transplanting islets encapsulated with CXCL12 restores blood sugar control without immunosuppression in animal models of diabetesAn approach developed by Massachusetts General Hospital (MGH)...
Published Studies Related to Thymoglobulin (Anti-Thymocyte Globulin)
Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. [2010.11]
BACKGROUND: We performed a randomized trial evaluating alemtuzumab, a humanized anti-CD52 monoclonal antibody, in living donor (LD) kidney transplantation. METHODS: Thirty-eight LD first renal transplant recipients were randomized into three single-agent antibody induction groups: thymoglobulin (group A); alemtuzumab (group B); and daclizumab (group C)...
Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. [2010.06.27]
BACKGROUND: To define the role of mammalian target of rapamycin inhibitors in kidney transplantation, we compared efficacy and safety of two immunosuppressive regimens-a calcineurin inhibitor-free regimen with depletive induction versus a calcineurin inhibitor-based regimen... CONCLUSION: Patients treated with induction plus SRL, mycophenolate mofetil, and corticosteroids may obtain good renal function but have a higher risk of adverse events, drug withdrawal, and graft loss.
A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation. [2010.01]
BACKGROUND: This study compared the safety and efficacy of early corticosteroid withdrawal (ECSWD) with rabbit anti-thymocyte globulin (rATG) induction to chronic corticosteroid therapy (CCST) without antibody induction in primary, living-donor renal transplant recipients... CONCLUSIONS: rATG with tacrolimus and MMF therapy may allow early elimination of corticosteroids, is associated with trends toward lower lipid levels, less weight gain, and a safety profile comparable to CCST therapy.
Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. [2009.11]
This randomized, comparative study assessed the long-term efficacy and tolerability of thymoglobulin (TMG) induction in 93 liver transplant patients with an initial regimen of tacrolimus (Tac), mycophenolate mofetil (MMF), and steroids. Forty-four patients were randomly allocated to the TMG+ group, and 49 patients were randomly allocated to the TMG- group...
A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. [2008.10.15]
BACKGROUND: Use of induction for renal transplantation is controversial because of the concerns about long-term safety and efficacy... CONCLUSIONS: This long-term follow-up showed that thymoglobulin was associated with higher event-free survival and improved QALYs, without increased posttransplant lymphoproliferative disorder or cytomegalovirus disease, compared with Atgam at 10 years.
Clinical Trials Related to Thymoglobulin (Anti-Thymocyte Globulin)
Low Dose Thymoglobin in Renal Transplant Patients [Recruiting]
This is a planned single center prospective randomized study evaluating the safety and
efficacy of low dose thymoglobulin as induction agent in renal transplant recipients.
Inclusion criteria will be adult renal transplant recipients who are not sensitized against
their potential donors. The patients who agree to participate in the study will be randomly
assigned to either thymoglobulin at 1. 25mg/kg x 3 doses or 0. 75mg/kg x 3 doses. There will
be 86 sealed envelopes to perform the randomization process. 43 envelopes with 1. 25mg/kg
dosing and the other 43 envelopes with 0. 75mg/kg dosing. The investigators will sequentially
choose the sealed envelopes at the time of the patient randomization process. All patients
will be started on our standard immunosupression regimen of prograf/cellcept and a fast
steroid taper. Data will be obtained from every patient for up to one year post-transplant.
Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome [Recruiting]
The goal of this clinical research study is to learn if combining the drugs thymoglobulin,
methylprednisolone, cyclosporine, and G-CSF (Neupogen or Neulasta) can help to control
severe aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS). The safety of
this combination therapy will also be studied.
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT [Recruiting]
One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal
Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem
cells to replace the tumor cells.
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT [Recruiting]
The primary goal of the study is to determine the incidence and severity of acute Graft
versus Host Disease (GVHD) following human leukocyte antigen (HLA) matched related donor
Hematopoetic Stem Cell(HSC) transplant in patients with blood related cancers who receive
the combination of tacrolimus and Thymoglobulin as GVHD prophylaxis. The investigators also
will determine the safety of this combination in the first six months post transplant.
Secondary goals include determining the time to recovery of white blood cells and platelets
(engraftment), determining the occurrence of opportunistic infections, defined as infection
that occurs in people with weakened immune systems and caused by organisms that do not
normally cause disease (fungal infections, pneumocystis carinii pneumonia (PCP), and viral
infections), estimating the incidence of chronic GVHD at two years and the overall and
disease free survival at two years.
Immune response will be assessed by means of immuno-correlative studies both prior to and at
various points after transplant.
Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin [Recruiting]
The purpose of this study is to determine the safety and feasibility of conditioning with
fludarabine, busulphan and thymoglobuline in patients with myelodysplastic syndrome (MDS),
myelodysplastic/myeloproliferative disorders (MDS/MPD) or acute myeloid leukaemia (AML)
undergoing haematopoietic stem cell allograft with granulocyte colony-stimulating factor
(G-CSF)-mobilised peripheral blood stem cells (PBSC) (or bone marrow) from HLA compatible
Reports of Suspected Thymoglobulin (Anti-Thymocyte Globulin) Side Effects
Febrile Neutropenia (111),
Acute Graft Versus Host Disease in Skin (92),
Acute Graft Versus Host Disease (66),
Cytomegalovirus Test Positive (64),
Chronic Graft Versus Host Disease (45), more >>